UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of December 2023
Commission File Number: 001-38024
BeyondSpring Inc.
BeyondSpring Inc.
28 Liberty Street, 39th Floor
New York, New York 10005
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
On December 18, 2023, BeyondSpring Inc. (the “Company”) issued a press release announcing the receipt of a letter from the Listing
Qualifications Department of The Nasdaq Stock Market LLC, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information contained in this report is hereby incorporated by reference into the Registration Statement on Form F-3, File No.
333-257639, and the Registration Statements on Form S-8, File No. 333-216639 and File No. 333-240082, of the Company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
| |
BeyondSpring Inc.
|
| |
|
| |
By:
|
/s/ Lan Huang
|
| |
Name: Lan Huang
|
| |
Title: Chairperson and Chief Executive Officer
|
| |
|
|
Date: December 18, 2023
|
|
EXHIBIT INDEX
|
Exhibit No.
|
Exhibit
|
| |
|
|
|
Press release, dated December 18, 2023.
|
Exhibit 99.1
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
NEW YORK, December 18, 2023 – BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring”
or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs,
today announced that on December 14, 2023, it received a written notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set
forth in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company’s ordinary shares (the “Ordinary Shares”) was below $1.00 per share for 31 consecutive business days. The notification letter does not result in the immediate
delisting of the Company’s Ordinary Shares and has no current immediate effect on the listing or trading of the Company’s Ordinary Shares on Nasdaq.
Pursuant to the Nasdaq Listing Rule 5810(c)(3)(A), the Company is provided with a compliance period of 180 calendar days from the date of the notification letter,
or until June 11, 2024, to regain compliance with the minimum bid price requirement. During this period, the Company’s Ordinary Shares will continue to trade on Nasdaq. If at any time before June 11, 2024, the bid price of the Company’s Ordinary
Shares closes at or above $1.00 per share for a minimum of ten consecutive trading days, Nasdaq will provide written confirmation of compliance and this matter will be closed. In the event the Company does not regain compliance by June 11, 2024,
subject to the determination by the staff of Nasdaq, the Company may be eligible for an additional 180-day compliance period.
The notification letter does not affect the Company’s business operations, and the Company is considering all available options to regain compliance with the
listing rules within the prescribed grace period.
About BeyondSpring
BeyondSpring (NASDAQ: BYSI) is a global clinical-stage biopharmaceutical company focused on developing innovative therapies to improve
clinical outcomes for patients with high unmet medical needs. The Company is advancing its first-in-class lead asset, Plinabulin, as a direct anti-cancer agent in various cancer indications and to prevent chemotherapy-induced neutropenia. Its
pipeline also includes three preclinical immuno-oncology assets. Additionally, BeyondSpring’s subsidiary, SEED Therapeutics, leverages a proprietary targeted protein degradation (TPD) drug discovery platform and has an initial R&D collaboration
with Eli Lilly. Learn more by visiting https://beyondspringpharma.com.
Investor Contact:
IR@beyondspringpharma.com
Media Contact:
PR@beyondspringpharma.com